Noradrenaline dysregulation plays a critical role in the pathophysiology of PTSD.
Noradrenaline and CRF may interact in regulating amygdala versus mPFC activation.
The α1 adrenergic receptor antagonist prazosin decreases many symptoms of PTSD.
Other alterations in noradrenergic signaling may also contribute to PTSD symptoms.
Evidence suggests heterogeneity in the role of noradrenergic dysregulation in PTSD.